RARRES2 and metabolic syndrome: Chemerin plasma levels increase in diabetes [8,9], increased visceral adiposity [10,11], dyslipidemia [12,13], and high blood pressure [14,15] independently but these positive correlations often become even more powerful in people diagnosed with metabolic syndrome [16–18].